Cancer Research Studies and Clinical Trials

 Study

Indication

 GS-US-595-6184 (ASCENT-05)

Randomized, open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After surgery and Neoadjuvant Therapy

CELC-G-302 (VIKTORIA-2)

A Randomized, Open-Label Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors with or Without Gedatolisib as First-Line Treatment in Patients with HR-Positive and HER2-Negative Advanced Breast Cancer

TEMPUS TIME TRIAL (GEMINI)

A Longitudinal Multiomic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer

Astra-Zeneca TROPION-Lung 10

Phase 3, Randomized, Open-Label Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for First-Line Treatment of Patients with Locally-advanced or Metastatic Non-Squamous NSCLC with High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

 Study

Indication

 BMS CA2390004 (KRYSTAL-4)

A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer with KRAS G12C Mutation

PFIZER C6461003

An Interventional, Phase 3, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of PF-08634404 in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Treatment-Naïve Participants with Metastatic Colon Cancer

BMS CA224-1093

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression ≥ 1%

 Study

Indication

 CELC-G-301 (VIKTORIA-1)

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy

LOXO-BTK-20019

Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell lymphoma (BRUIN MCL-321)

 Study

Indication

 MT2221

Study of Fresh Bone Marrow in patients with Multiple Myeloma Cancer with active disease >5% plasma cells

MT1410-A

Evaluate Molecular Characteristics in the blood samples of patients with Ovarian or Pancreas—Any Stage Pre-TX/Surgery

MT2875

Study of Fresh Blood & Urine from Patients with Pancreatic Cancer

MT0332

Study of Frozen Plasma and Buffy Coat from Patients with Stage IV NSCLC Receiving Immunotherapy

MT1118

Study of Fresh Blood from Patients with Stage III-IV Breast Cancer, Colon Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, or Melanoma

MT4901

This study is designed to evaluate biomarkers in biospecimens collected from patients with Non-Small Cell Lung Cancer

MT2234

This study is designed to evaluate biomarkers associated with cancer for diagnostic assay development.

MT7030

This is a prospective study designed to evaluate biomarkers in biospecimens collected from patients with colorectal cancer (CRC).

MT1821

This is a prospective study to evaluate biomarkers/molecular characteristics in blood from patients diagnosed with various cancers